Beta-Blocker

Beta-blockers may reduce risk for death or hospitalization for people with HF with preserved ejection fraction more effectively than calcium channel blockers, according to data from a meta-analysis of randomized controlled trials.

Renal denervation lowered blood pressure out to 36 months, regardless of baseline antihypertensive class combinations and polypharmacy burden, according to an analysis of the Global SYMPLICITY Registry DEFINE.

Compared with nonuse, beta-blockers were linked to an 8% reduction in major CV events among patients with obstructive CAD referred for invasive testing, according to data published in the Journal of the American College of Cardiology.

PHILADELPHIA — In patients with HF with reduced ejection fraction, the four pillars of optimal medical therapy should be started as soon as possible, a speaker said here.

Rapid uptitration of medical therapy early after hospitalization for acute HF improves prognosis independent of left ventricular ejection fraction, according to a prespecified analysis of the STRONG-HF trial.

Defining eligibility criteria for initiation of guideline-directed medical therapy and new HF agents.

Communication between cardiologists and general practitioners during the treatment of patients with non-acute chest pain was “suboptimal,” according to researchers.

The majority of patients admitted for acute HF are eligible for foundational quadruple therapy and other medications, researchers reported in JACC: Heart Failure.

Among patients who underwent transcatheter aortic valve replacement, those who filled prescriptions for statins and ACE inhibitors or angiotensin receptor blockers had lower mortality risk at 3 years vs. those who did not, data show.

Patients with COPD experienced early, but modest and nonpersistent, reductions in lung function during treatment with metoprolol, according to a post-hoc analysis of the BLOCK COPD study in The Annals of the American Thoracic Society.